Hematopoietic Stem Cell Transplantation Clinical Trial
Official title:
Investigation of Pulmonary Rehabilitation on Exercise Capacity, Physical Activity Level, Respiratory Muscle Strength and Endurance During Transplantation Process in Hematopoietic Stem Cell Transplantation Recipients
Stem cell transplantation is a process in which stem cells are harvested from either a patient's or donor's bone morrow or peripheral blood for intravenous infusion. Hematopoietic stem cell transplantation is a treatment with a high curative potential that may benefit a great number of patients with hematological, oncological, immunologic and hereditary diseases. In contrast, there are significant risks of chronic and acute complications due to conditioning regimens and immunosuppression, toxicity infections, graft versus host disease (GVHD) and inactivity including being bedridden. Patients undergoing hematopoietic stem cell transplantation are exposed to risk factors due to chemotherapy, whole body radiation, high dose corticosteroids, treatment-related inactivity, transplantation and GVHD-related muscle damage. Direct toxicity of the cardiovascular and musculoskeletal system (left ventricular dysfunction, pulmonary fibrosis) in relation to hematopoietic stem cell transplantation and secondary indirect physiological consequences of treatment such as exercise intolerance, sarcopenia are seen. In literature, there are few studies showing that aerobic exercise and resistance training applied during and after the transplantation process has positive effects on muscle strength and endurance, fatigue, functional performance, quality of life and physical activity. It has been shown in the literature that inspiratory muscle training in allogeneic hematopoietic stem cell transplant recipients increases functional exercise capacity, inspiratory and expiratory muscle strength, and reduces effort dyspnea perception, but the effects of inspiratory muscle training during transplantation have not been investigated. There are no studies showing long-term follow-up of comprehensive cardiopulmonary rehabilitation program during hematopoietic stem cell transplantation and which of these outcome measures are survival effect. Therefore, the investigators aimed to investigate the effect of cardiopulmonary rehabilitation on hematopoietic stem cell transplantation in terms of exercise capacity, respiratory and peripheral muscle strength, respiratory muscle endurance, respiratory function, physical activity level, fatigue, depression and quality of life effects and the effect of these outcome measures on survival.
According to sample size calculation 20 patients scheduled for hematopoietic stem cell transplantation will be included. Patients scheduled for hematopoietic stem cell transplantation will be evaluated four times; pre-transplantation, post-transplantation, 100th day after transplantation and 1st year after transplantation. Recipients will be randomized into study and control groups. Cardiopulmonary rehabilitation programme includes inspiratory muscle training, upper extremity aerobic exercise, progressive resistance training will be performed study groups. Upper extremity aerobic exercise and progressive resistance training will be performed control groups. Exercise capacity, physical activity, pulmonary functions, respiratory and peripheral muscle strength, respiratory muscle endurance, dyspnea and fatigue perception, depression and quality of life will be evaluated. Primary outcome measurements are exercise capacity and which outcome measures influence survival. Secondary outcomes are respiratory and peripheral muscle strength, respiratory muscle endurance, pulmonary functions, physical activity, dyspnea and fatigue perception, depression and quality of life. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00766883 -
Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT06148610 -
Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support
|
||
Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
Completed |
NCT02564458 -
Fitness in Allogeneic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT02543073 -
MSC for Treatment of Interstitial Lung Disease After Allo-HSCT
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT01714557 -
Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Completed |
NCT00023530 -
Blood and Marrow Transplant Clinical Research Network
|
N/A | |
Recruiting |
NCT04092309 -
Effect of Angiotensin Converting Enzyme and Sacubitril Valsartan in Patients After Bone Marrow Transplantation
|
N/A | |
Completed |
NCT00000603 -
Cord Blood Stem Cell Transplantation Study (COBLT)
|
Phase 2 | |
Completed |
NCT02663622 -
Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)
|
Phase 2 | |
Recruiting |
NCT04937634 -
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT04203108 -
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
|
Phase 4 | |
Withdrawn |
NCT03279133 -
Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.
|
Phase 4 | |
Completed |
NCT03654599 -
Effects of Digital Stories Intervention on Psychosocial Well-being
|
N/A | |
Completed |
NCT05151406 -
Myths and Misconceptions About HSCT in a Limited Resource Region
|
N/A | |
Completed |
NCT02241005 -
Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci
|
N/A | |
Recruiting |
NCT03689465 -
PTCy-ATG vs ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
|
Phase 4 | |
Recruiting |
NCT04868786 -
Pharmacokinetics and Pharmacodynamics of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT03010579 -
Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation
|
Phase 4 |